These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9681700)

  • 1. Higher haematocrit levels: do they improve patient outcomes, and are they cost effective?
    Collins AJ; Keane WF
    Nephrol Dial Transplant; 1998 Jul; 13(7):1627-9. PubMed ID: 9681700
    [No Abstract]   [Full Text] [Related]  

  • 2. Anemia management in patients with chronic renal insufficiency.
    Kausz AT; Obrador GT; Pereira BJ
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S39-51. PubMed ID: 11118157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 4. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful.
    Junor BJ
    Perit Dial Int; 1993; 13 Suppl 2():S535-7. PubMed ID: 8399658
    [No Abstract]   [Full Text] [Related]  

  • 5. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 7. Target haematocrit during erythropoietin treatment in dialysis patients. Which value is 'true-functional haematocrit'?
    Vlassopoulos D; Sonikian M; Dardioti V; Hadjiconstantinou V
    Nephrol Dial Transplant; 1999 May; 14(5):1340-1. PubMed ID: 10344405
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity--the experience of the Lombardy Dialysis Registry.
    Locatelli F; Conte F; Marcelli D
    Nephrol Dial Transplant; 1998 Jul; 13(7):1642-4. PubMed ID: 9681705
    [No Abstract]   [Full Text] [Related]  

  • 9. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 10. [Review of the scientific evidence of the efficiency of erythropoietin use].
    García-Altés A; Puig-Junoy J
    Med Clin (Barc); 2006 Sep; 127(11):415-20. PubMed ID: 17020686
    [No Abstract]   [Full Text] [Related]  

  • 11. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human erythropoietin for anaemia associated with chronic renal failure in predialysis patients.
    Schaefer RM; Schaefer L; Heidland A
    Przegl Lek; 1992; 49(1-2):41-2. PubMed ID: 1455005
    [No Abstract]   [Full Text] [Related]  

  • 13. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis].
    Fernández-Gallego J; Gutiérrez C
    Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoietin in pregnancies complicated by severe anemia of renal failure.
    Yankowitz J; Piraino B; Laifer SA; Frassetto L; Gavin L; Kitzmiller JL; Crombleholme W
    Obstet Gynecol; 1992 Sep; 80(3 Pt 2):485-8. PubMed ID: 1495715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemoglobin levels, quality of life, and survival.
    Sadler JH; Meyer KB
    Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report.
    Salim KA; Salim S; Mathew T
    J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case management of the anemic patient. Epoetin alfa: focus on hematocrit.
    Kirlin L
    ANNA J; 1992 Feb; 19(1):66-7. PubMed ID: 1546890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
    To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
    Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
    [No Abstract]   [Full Text] [Related]  

  • 19. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.